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Abstract
© 2018 FASEB.  Autosomal-dominant  polycystic  kidney disease (ADPKD)  is  associated with
progressive formation of renal cysts, kidney enlargement, hypertension, and typically end-stage
renal disease. In ADPKD, inherited mutations disrupt functionofthe polycystins (encoded byPKD1
and PKD2),  thus causing loss of  a cyst-repressive signal  emanating from the renal  cilium.
Genetic studies have suggested ciliary maintenance is essential for ADPKD pathogenesis. Heat
shock protein 90 (HSP90) clients include multiple proteins linked to ciliary maintenance. We
determined that ganetespib, a clinical HSP90 inhibitor, inhibited proteasomal repression of NEK8
and the Aurora-A activator trichoplein, rapidly activating Aurora-A kinase and causing ciliary loss
in vitro. Using conditional mouse models for ADPKD, we performed long-term (10 or 50 wk)
dosing experiments that demonstrated HSP90 inhibition caused durable in vivo loss of cilia,
controlled  cystic  growth,  and  ameliorated  symptoms  induced  by  loss  of  Pkd1  or
Pkd2.Ganetespib efficacy was not increased by combination with 2-deoxy-D-glucose, aglycolysis
inhibitor showing some promise for ADPKD. These studies identify a new biologic activity for
HSP90 and support a cilia-based mechanism for cyst repression.
http://dx.doi.org/10.1096/fj.201700909R
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